Jia Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jia Yan has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Magdalena Walkiewicz
Centralized Sequencing Program National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda Maryland USA
5 shared publications- Morgan Similuk
Centralized Sequencing Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland
5 shared publications Wenjia Cao
Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
4 shared publicationsRajarshi Ghosh
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
3 shared publicationsAlexandra F. Freeman
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
2 shared publications- Breanna Beers
Postbaccalaureate Fellow/National Institute of Allergy and Infectious Diseases, National Institutes of Health
2 shared publications
Latest Publications
- 27 February 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 157 (6) , 1457-1460
Additive effects of common and rare genetic variants on inflammatory bowel disease risk in a cohort with immunodeficiency
- 27 February 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 157 (6) , 1457-1460
Additive effects of common and rare genetic variants on inflammatory bowel disease risk in a cohort with immunodeficiency
- Open Access
- 10 July 2024
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (2)
Psychological state at the time of psychiatric genetic counseling impacts patient empowerment: A pre–post analysis
Psychiatric genetic counseling (GC) has been associated with patient‐reported increases in empowerment (perceived control, emotional regulation, and hope). We sought to evaluate the extent to which patients' psychological state at the time of GC is related to changes in empowerment. Participants with a history of major depressive disorder and/or bipolar disorder that had been refractory to treatment underwent psychiatric GC remotely from 2022 to 2023. GC was performed by four genetic counselors and included discussion of perceived causes of illness, multifactorial inheritance, and protective factors. Empowerment, depression, and anxiety were measured immediately prior to GC via online survey by the GCOS‐16, PHQ‐9, and GAD‐7, respectively. Empowerment was re‐assessed 2 weeks later. In total, 66/161 (41.0%) invited individuals completed both the baseline and follow‐up surveys. Participants completing both surveys were 54.6% female, 84.8% white, and ranged in age from 22 to 78 years (mean = 54.8 years). Overall, a significant change in mean empowerment was not observed (p = 0.38); however, there were moderating effects by baseline psychological state. A multiple linear regression model incorporating PHQ‐9, GAD‐7 and baseline GCOS‐16 score predicted change in empowerment with a large effect (F = 5.49, R2 = 0.21, p < 0.01). A higher score on the PHQ‐9 was associated with decreases in empowerment from pre to post GC. Higher scores on the GAD‐7 and lower baseline GCOS‐16 scores were associated with increases in empowerment. Further, two‐way ANOVA was conducted to assess change in empowerment between subgroups based on the level of anxiety and depression. Those with low depression and high anxiety reported significant increases in empowerment (F = 6.64, p = 0.01). These findings suggest that psychiatric GC may be especially helpful to individuals experiencing anxiety and low baseline empowerment. Alternative approaches may be needed to best meet the needs of those experiencing significant depression.
- 10 July 2024
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (2)
Open AccessPsychological state at the time of psychiatric genetic counseling impacts patient empowerment: A pre–post analysis
Psychiatric genetic counseling (GC) has been associated with patient‐reported increases in empowerment (perceived control, emotional regulation, and hope). We sought to evaluate the extent to which patients' psychological state at the time of GC is related to changes in empowerment. Participants with a history of major depressive disorder and/or bipolar disorder that had been refractory to treatment underwent psychiatric GC remotely from 2022 to 2023. GC was performed by four genetic counselors and included discussion of perceived causes of illness, multifactorial inheritance, and protective factors. Empowerment, depression, and anxiety were measured immediately prior to GC via online survey by the GCOS‐16, PHQ‐9, and GAD‐7, respectively. Empowerment was re‐assessed 2 weeks later. In total, 66/161 (41.0%) invited individuals completed both the baseline and follow‐up surveys. Participants completing both surveys were 54.6% female, 84.8% white, and ranged in age from 22 to 78 years (mean = 54.8 years). Overall, a significant change in mean empowerment was not observed (p = 0.38); however, there were moderating effects by baseline psychological state. A multiple linear regression model incorporating PHQ‐9, GAD‐7 and baseline GCOS‐16 score predicted change in empowerment with a large effect (F = 5.49, R2 = 0.21, p < 0.01). A higher score on the PHQ‐9 was associated with decreases in empowerment from pre to post GC. Higher scores on the GAD‐7 and lower baseline GCOS‐16 scores were associated with increases in empowerment. Further, two‐way ANOVA was conducted to assess change in empowerment between subgroups based on the level of anxiety and depression. Those with low depression and high anxiety reported significant increases in empowerment (F = 6.64, p = 0.01). These findings suggest that psychiatric GC may be especially helpful to individuals experiencing anxiety and low baseline empowerment. Alternative approaches may be needed to best meet the needs of those experiencing significant depression.
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 139
Variable Clinical Presentation in Individuals with Truncating Variants in DDX41
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 139
Variable Clinical Presentation in Individuals with Truncating Variants in DDX41
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 25-26
High rate of molecular diagnosis among individuals with alopecia with known or suspected inborn errors of immunity
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 25-26
High rate of molecular diagnosis among individuals with alopecia with known or suspected inborn errors of immunity
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 54-55
Chromosomal microarray analysis reveals copy number variants contribute to disease in children with suspected inborn errors of immunity
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 54-55
Chromosomal microarray analysis reveals copy number variants contribute to disease in children with suspected inborn errors of immunity
- Open Access
- 23 November 2022
- Published by Springer Nature in Research Square
Chromosomal Microarray Analysis Supplements Exome Sequencing to Diagnose Children with Suspected Inborn Errors of Immunity
Purpose: Though copy number variants (CNVs) have been suggested to play a significant role in inborn errors of immunity (IEI), the precise nature of this role remains largely unexplored. Thus, we sought to determine the diagnostic contribution of CNVs using genome-wide chromosomal microarray analysis (CMA) in children with suspected or known IEI. Methods: We performed exome sequencing (ES) and CMA for 332 unrelated pediatric probands referred for evaluation of IEI. The analysis included primary, secondary, and incidental findings. Results: Of the 332 probands, 134 (40.4%) received molecular diagnoses. Of these, 116/134 (86.6%) were diagnosed by ES alone. An additional 15/134 (11.2%) were diagnosed by CMA alone, including two likely de novochanges. Three (2.2%) participants had diagnostic molecular findings from both ES and CMA, including two compound heterozygotes and one patient with two distinct diagnoses. Half of the participants with CMA contribution to diagnosis had CNVs in at least one non-immune gene, highlighting the clinical complexity of these cases. Overall, CMA contributed to 18/134 diagnoses (13.4%), increasing the overall diagnostic yield by 15.5%. Conclusion: Pairing ES and CMA can provide a comprehensive evaluation to clarify the complex factors that contribute to both immune and non-immune phenotypes. Such a combined approach to genetic testing helps untangle complex phenotypes, not only by clarifying the differential diagnosis, but in some cases by identifying multiple diagnoses contributing to the overall clinical presentation.
- 23 November 2022
- Published by Springer Nature in Research Square
Open AccessChromosomal Microarray Analysis Supplements Exome Sequencing to Diagnose Children with Suspected Inborn Errors of Immunity
Purpose: Though copy number variants (CNVs) have been suggested to play a significant role in inborn errors of immunity (IEI), the precise nature of this role remains largely unexplored. Thus, we sought to determine the diagnostic contribution of CNVs using genome-wide chromosomal microarray analysis (CMA) in children with suspected or known IEI. Methods: We performed exome sequencing (ES) and CMA for 332 unrelated pediatric probands referred for evaluation of IEI. The analysis included primary, secondary, and incidental findings. Results: Of the 332 probands, 134 (40.4%) received molecular diagnoses. Of these, 116/134 (86.6%) were diagnosed by ES alone. An additional 15/134 (11.2%) were diagnosed by CMA alone, including two likely de novochanges. Three (2.2%) participants had diagnostic molecular findings from both ES and CMA, including two compound heterozygotes and one patient with two distinct diagnoses. Half of the participants with CMA contribution to diagnosis had CNVs in at least one non-immune gene, highlighting the clinical complexity of these cases. Overall, CMA contributed to 18/134 diagnoses (13.4%), increasing the overall diagnostic yield by 15.5%. Conclusion: Pairing ES and CMA can provide a comprehensive evaluation to clarify the complex factors that contribute to both immune and non-immune phenotypes. Such a combined approach to genetic testing helps untangle complex phenotypes, not only by clarifying the differential diagnosis, but in some cases by identifying multiple diagnoses contributing to the overall clinical presentation.
- Open Access
- 7 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (13) , 3974-3978
The contribution of rare copy number variants in FAS toward pathogenesis of autoimmune lymphoproliferative syndrome
Autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic nonmalignant lymphadenopathy, splenomegaly, cytopenias, and other autoimmune manifestations. ALPS is caused by lymphocyte accumulation from defects in FAS-mediated apoptosis. Heterozygous germline or somatic pathogenic single nucleotide variants in FAS are the most common molecular etiology of ALPS. Through the Centralized Sequencing Program at the National Institute of Allergy and Infectious Diseases, we performed exome sequencing on subjects with a clinical diagnosis of ALPS, with a subset receiving copy number variant (CNV) analysis. In this cohort, we identified 3 subjects from unrelated families with CNVs at the FAS locus. One subject had a de novo ∼0.828 Mb copy number loss encompassing all of FAS. The second subject had a maternally inherited ∼1.004 Mb copy number loss encompassing all of FAS. The third subject had a paternally inherited ∼0.044 Mb copy number loss encompassing exons 7 through 9 of FAS. Subjects with deletions in FAS had clinical presentations and biomarker profiles similar to those with ALPS and with germline and somatic FAS variants. We demonstrate that CNV analysis should be pursued if there is clinical and biomarker evidence of ALPS because it can lead to a molecular diagnosis and appropriate treatment when FAS sequencing is inconclusive.
- 7 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (13) , 3974-3978
Open AccessThe contribution of rare copy number variants in FAS toward pathogenesis of autoimmune lymphoproliferative syndrome
Autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic nonmalignant lymphadenopathy, splenomegaly, cytopenias, and other autoimmune manifestations. ALPS is caused by lymphocyte accumulation from defects in FAS-mediated apoptosis. Heterozygous germline or somatic pathogenic single nucleotide variants in FAS are the most common molecular etiology of ALPS. Through the Centralized Sequencing Program at the National Institute of Allergy and Infectious Diseases, we performed exome sequencing on subjects with a clinical diagnosis of ALPS, with a subset receiving copy number variant (CNV) analysis. In this cohort, we identified 3 subjects from unrelated families with CNVs at the FAS locus. One subject had a de novo ∼0.828 Mb copy number loss encompassing all of FAS. The second subject had a maternally inherited ∼1.004 Mb copy number loss encompassing all of FAS. The third subject had a paternally inherited ∼0.044 Mb copy number loss encompassing exons 7 through 9 of FAS. Subjects with deletions in FAS had clinical presentations and biomarker profiles similar to those with ALPS and with germline and somatic FAS variants. We demonstrate that CNV analysis should be pursued if there is clinical and biomarker evidence of ALPS because it can lead to a molecular diagnosis and appropriate treatment when FAS sequencing is inconclusive.
- 1 December 2021
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 56 (12) , 2286-2294
Multiple, independent, common variants at RET, SEMA3 and NRG1 gut enhancers specify Hirschsprung disease risk in European ancestry subjects
- 1 December 2021
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 56 (12) , 2286-2294
Multiple, independent, common variants at RET, SEMA3 and NRG1 gut enhancers specify Hirschsprung disease risk in European ancestry subjects